+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories



Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories



BrachyTherapy 14(6): 766-772



To determine whether a previously reported substratification system can be extrapolated to patients with high-risk prostate cancer treated with permanent interstitial brachytherapy. Four hundred six National Comprehensive Cancer Network patients with high-risk prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiotherapy were stratified into good (prostate-specific antigen >20 or Gleason score ≥8 or ≥T3), intermediate (prostate-specific antigen >20 and ≥T3), and poor (Gleason score ≥8 with ≥1 additional high-risk feature) prognostic cohorts. Because of only 1 patient with intermediate high-risk disease, the analysis was performed on patients in the good and poor cohorts. Biochemical failure (BF), prostate cancer-specific mortality (PCSM), distant metastasis, and overall mortality were assessed as function of prognostic group. Multiple parameters were evaluated for impact on outcome. With a median followup time of 7.9 years, 10- and 14-year rates of BF and PCSM for the entire cohort were 7.8% and 3.7%, respectively. The BF rate was significantly greater in the poor prognostic category (16.8% vs. 7.8%, p = 0.041). The poor prognostic category was the strongest predictor of BF in univariate and multivariate analyses. No statistically significant differences in PCSM, distant metastasis, or overall mortality were identified between the good and poor prognostic categories. Patients with high-risk prostate cancer treated with a brachytherapy approach have excellent long-term biochemical control and cancer-specific survival. The poor prognostic high-risk category had a higher rate of BF compared with the good prognostic category without a higher rate of PCSM or distant metastasis.

(PDF emailed within 0-6 h: $19.90)

Accession: 059169746

Download citation: RISBibTeXText

PMID: 26489923

DOI: 10.1016/j.brachy.2015.09.003


Related references

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA. Journal of Contemporary BrachyTherapy 9(4): 297-303, 2017

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. BrachyTherapy 2018, 2018

Permanent Prostate Brachytherapy for Organ Confined High-Risk Prostate Cancer Patients. BrachyTherapy 12: S65-S66, 2013

Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis. World Journal of Urology 31(6): 1511-1517, 2014

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 73(2): 341-346, 2008

Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. Bju International 107(2): 226-232, 2011

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110(3): 551-555, 2007

Biochemical outcomes following hormonal therapy, Pd-103 prostate brachytherapy and 3D conformal external beam irradiation in the treatment of high risk prostate cancer. International Journal of Radiation Oncology Biology Physics 54(2 Supplement): 271, 2002

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. Journal of Urology 173(5): 1562-1566, 2005

12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. Journal of Urology 179(5 Suppl): S20-S24, 2008

Permanent prostate brachytherapy for high-risk prostate cancer. BrachyTherapy 6(2): 78-79, 2007

Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer 124(17): 3528-3535, 2018

Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology, Biology, Physics 100(2): 374-382, 2017

Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics 94(4): 657-666, 2016

Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients. International Journal of Radiation Oncology*biology*physics 93(3): E213-E214, 2015